Video

Genomic testing in prostate cancer and personalized medicine

Author(s):

Urology Times staff

“The…state of genomic testing continues to evolve,” says Ketan K. Badani, MD.

In this video, Ketan K. Badani, MD, also shares what personalized medicine means to him. Badani is a professor of urology at Icahn School of Medicine at Mount Sinai, vice chairman of urology and robotic operations at Mount Sinai Health System, director of robotic surgery at Mount Sinai West, and the director of the Comprehensive Kidney Cancer Program At Mount Sinai Health System, New York.

Related Videos
Man talking with doctor | Image Credit: © RFBSIP - stock.adobe.com
Andrew C. Peterson, MD, MPH, answers a question during a Zoom interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
Survey sheds light on international genetic testing patterns in prostate cancer
November 18th 2024

Survey sheds light on international genetic testing patterns in prostate cancer

Hannah Clarke
Data demonstrated wide variation in the proportion of patients recommended for testing and showed that barriers to testing remain.
Variants of unknown significance may adversely affect RARP outcomes
November 11th 2024

Variants of unknown significance may adversely affect RARP outcomes

Hannah Clarke
In total, 33.3% of patients with a VUS also had positive lymph node involvement and required adjuvant ADT compared with only 16.2% of patients who did not have a VUS.
Genetic testing in prostate cancer is increasing over time, data suggests
November 11th 2024

Genetic testing in prostate cancer is increasing over time, data suggests

Hannah Clarke
“It is critical that urologists understand when to order germline testing, are comfortable with actually ordering these tests, and integrate medical geneticists when appropriate," says Aditya Bagrodia, MD, FACS.
Genomic risk model validated for prostate cancer risk prediction
November 6th 2024

Genomic risk model validated for prostate cancer risk prediction

Hannah Clarke
Patients with high P-CARE scores had an increased risk of any, metastatic, and fatal prostate cancer compared with patients with median P-CARE scores.
Circulating tumor cell count may serve as a prognostic biomarker in mHSPC
October 8th 2024

Circulating tumor cell count may serve as a prognostic biomarker in mHSPC

Hannah Clarke
Patients with elevated CTC count at baseline experienced poor complete response rates and worsened PFS and OS.
NSD1/2 may serve as potential therapeutic targets in prostate cancer
September 11th 2024

NSD1/2 may serve as potential therapeutic targets in prostate cancer

Hannah Clarke
“NSD2 is a cancer specific collaborator of the androgen receptor that essentially rewires its activity to support prostate cancer development," says Abhijit Parolia, PhD,
© 2024 MJH Life Sciences

All rights reserved.